Literature DB >> 31536818

Multistate population and whole genome sequence-based strain surveillance of invasive pneumococci recovered in the USA during 2017.

J Varghese1, S Chochua2, T Tran1, H Walker1, Z Li1, P M Snippes Vagnone3, R Lynfield4, L McGee2, Y Li2, B J Metcalf2, T Pilishvili2, B Beall5.   

Abstract

OBJECTIVES: We aimed to provide population-based and whole-genome sequence (WGS) -based characterization of invasive pneumococcal disease isolates collected from multistate surveillance in the USA during 2017.
METHODS: We obtained short-read WGS from 2881 isolates with associated bioinformatics pipeline strain feature predictions. For quality control, capsular serotypes and antimicrobial MICs were also obtained conventionally from 442 isolates. Annotated WGS were provided (inclusive of serotypes, MICs, multilocus sequence types, pilus type(s)) from 2723 isolates. For 158 isolates with suboptimal WGS, antimicrobial MICs were obtained conventionally.
RESULTS: There were 127 isolates from children <5 years of age and 2754 isolates from those ≥5 years old in 2017. One of 43 different serotypes was predicted for 2877 of the 2881 isolates. Serotypes in the 13-valent conjugate vaccine together with 6C (PCV13+6C) accounted for 816 (28.3%) isolates, with PCV13 serotype 3 being the most common serotype overall. Non-PCV13-6C- serotypes accounted for 2065 (71.7%) isolates, comprising 96 (75.6%) isolates from children < 5 years old and 1969 (61.4%) isolates from those aged ≥5 years. Of 36 different categories of recently emerged serotype-switch variants, three showed marked increases relative to 2015-2016 in that the number from 2017 surpassed the number from 2015-2016 combined. Two of these included antimicrobial-resistant serotype 11A and 35B serotype-switch variants of the ST156 clonal complex.
CONCLUSIONS: PCV13+6C strains are still identified in 2017 but non-PCV13-type strains impose a considerable burden. This well-annotated year 2017 WGS/strain data set will prove useful for a broad variety of analyses and improved our understanding of invasive pneumococcal disease-causing strains in the post-PCV13 era. Published by Elsevier Ltd.

Entities:  

Keywords:  Capsular serotypes; Clonal complexes; Invasive pneumococcal disease incidence; Resistance features; Serotype switch variants

Year:  2019        PMID: 31536818     DOI: 10.1016/j.cmi.2019.09.008

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  9 in total

1.  Structural, Genetic, and Serological Elucidation of Streptococcus pneumoniae Serogroup 24 Serotypes: Discovery of a New Serotype, 24C, with a Variable Capsule Structure.

Authors:  Feroze Ganaie; Karsten Maruhn; Chengxin Li; Richard J Porambo; Pernille L Elverdal; Chitrananda Abeygunwardana; Mark van der Linden; Jens Ø Duus; Carmen L Sheppard; Moon H Nahm
Journal:  J Clin Microbiol       Date:  2021-06-18       Impact factor: 5.948

2.  Estimates of the Health and Economic Burden of Pneumococcal Infections Attributable to the 15-Valent Pneumococcal Conjugate Vaccine Serotypes in the USA.

Authors:  Kwame Owusu-Edusei; Arijita Deb; Kelly D Johnson
Journal:  Infect Dis Ther       Date:  2022-01-27

3.  Large-scale genomic analysis of antimicrobial resistance in the zoonotic pathogen Streptococcus suis.

Authors:  Nazreen F Hadjirin; Eric L Miller; Gemma G R Murray; Phung L K Yen; Ho D Phuc; Thomas M Wileman; Juan Hernandez-Garcia; Susanna M Williamson; Julian Parkhill; Duncan J Maskell; Rui Zhou; Nahuel Fittipaldi; Marcelo Gottschalk; A W Dan Tucker; Ngo Thi Hoa; John J Welch; Lucy A Weinert
Journal:  BMC Biol       Date:  2021-09-07       Impact factor: 7.431

4.  Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV.

Authors:  Lerato Mohapi; Yvett Pinedo; Olayemi Osiyemi; Khuanchai Supparatpinyo; Winai Ratanasuwan; Jean-Michel Molina; Ron Dagan; Gretchen Tamms; Tina Sterling; Ying Zhang; Alison Pedley; Jon Hartzel; Yanqing Kan; Kim Hurtado; Luwy Musey; Jakub K Simon; Ulrike K Buchwald
Journal:  AIDS       Date:  2022-03-01       Impact factor: 4.177

5.  Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in Korea and Hong Kong.

Authors:  Salini Mohanty; Tianyan Hu; GyongSeon Yang; Tsz K Khan; Kwame Owusu-Edusei; Isaya Sukarom
Journal:  Hum Vaccin Immunother       Date:  2022-04-14       Impact factor: 4.526

6.  A Multicenter Evaluation of Trends in Antimicrobial Resistance Among Streptococcus pneumoniae Isolates From Adults in the United States.

Authors:  Salini Mohanty; Kelly D Johnson; Kalvin C Yu; Janet A Watts; Vikas Gupta
Journal:  Open Forum Infect Dis       Date:  2022-09-02       Impact factor: 4.423

7.  Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants.

Authors:  Johnna Perdrizet; Carlos Felipe S Santana; Thais Senna; Rodrigo Fernandes Alexandre; Rodrigo Sini de Almeida; Julia Spinardi; Matt Wasserman
Journal:  Hum Vaccin Immunother       Date:  2020-09-23       Impact factor: 3.452

8.  Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU).

Authors:  Randall Severance; Howard Schwartz; Ron Dagan; Laurie Connor; Jianing Li; Alison Pedley; Jonathan Hartzel; Tina M Sterling; Katrina M Nolan; Gretchen M Tamms; Luwy K Musey; Ulrike K Buchwald
Journal:  Hum Vaccin Immunother       Date:  2021-11-02       Impact factor: 3.452

9.  Upsurge of Conjugate Vaccine Serotype 4 Invasive Pneumococcal Disease Clusters Among Adults Experiencing Homelessness in California, Colorado, and New Mexico.

Authors:  Bernard Beall; Hollis Walker; Theresa Tran; Zhongya Li; Jasmine Varghese; Lesley McGee; Yuan Li; Benjamin J Metcalf; Ryan Gierke; Emily Mosites; Sopio Chochua; Tamara Pilishvili
Journal:  J Infect Dis       Date:  2021-04-08       Impact factor: 5.226

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.